Biocon Limited

NSEI:BIOCON 株式レポート

時価総額：₹673.2b

Biocon 過去の業績

過去 基準チェック /16

Bioconは、平均年間2.7%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間13.7% 18.5%収益成長率で 成長しています。 Bioconの自己資本利益率は1%であり、純利益率は2.3%です。

主要情報

2.69%

収益成長率

1.89%

EPS成長率

Biotechs 業界の成長5.13%
収益成長率18.53%
株主資本利益率1.01%
ネット・マージン2.28%
前回の決算情報31 Mar 2026

最近の業績更新

分析記事 • May 21

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
分析記事 • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...

Recent updates

ナラティブの更新 • Jun 01

BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside

Analysts have nudged their fair value estimate for Biocon slightly higher to about ₹299 from roughly ₹296, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. The rationale is informed by recent Street research on peer companies that highlights the impact of tougher macro conditions, underappreciated balance sheet items and potential margin improvements under refreshed management teams.
分析記事 • May 21

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
ナラティブの更新 • May 03

BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside

Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
ナラティブの更新 • Apr 19

BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry

Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.
ナラティブの更新 • Apr 05

BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside

Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
ナラティブの更新 • Mar 21

BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals

Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.
ナラティブの更新 • Mar 07

BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals

Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.
ナラティブの更新 • Feb 21

BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns

Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.
ナラティブの更新 • Feb 07

BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns

Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).
ナラティブの更新 • Jan 23

BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside

Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).
ナラティブの更新 • Jan 09

BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns

Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).
ナラティブの更新 • Dec 26

BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns

Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.
分析記事 • Dec 25

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...
ナラティブの更新 • Dec 12

BIOCON: Future Share Dilution Risk Will Likely Pressure Returns

Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).
分析記事 • Dec 07

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...
ナラティブの更新 • Nov 27

BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks

Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.
分析記事 • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...
ナラティブの更新 • Nov 13

BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance

Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
ナラティブの更新 • Oct 05

Biosimilars Demand Will Unlock Global Market Opportunities

Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
分析記事 • Sep 22

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
分析記事 • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
分析記事 • Aug 04

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
分析記事 • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...
分析記事 • Jun 18

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
User avatar
新しいナラティブ • Dec 12

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

収支内訳

Biocon の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NSEI:BIOCON 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
31 Mar 26169,2703,85635,080-1,137
31 Dec 25168,2746,04237,604-1,379
30 Sep 25164,7584,85536,090-1,189
30 Jun 25157,7073,85035,755-1,501
31 Mar 25152,61710,13334,978-1,476
31 Dec 24147,6188,04332,633-1,843
30 Sep 24148,94114,39234,323-1,515
30 Jun 24147,66015,80830,286-1,110
31 Mar 24147,55710,22528,525-838
31 Dec 23146,12512,00226,439-119
30 Sep 23135,9994,98424,819-1,238
30 Jun 23124,5734,19723,998-2,156
31 Mar 23111,7424,62723,331-3,922
31 Dec 2298,0913,88122,558-5,606
30 Sep 2290,4226,17021,920-5,825
30 Jun 2285,6297,08421,305-5,768
31 Mar 2281,8406,48420,539-4,764
31 Dec 2175,8006,72720,252-4,050
30 Sep 2172,6326,54219,935-3,581
30 Jun 2171,7266,85219,466-3,530
31 Mar 2171,4317,40517,485-3,507
31 Dec 2068,9135,99616,778-3,607
30 Sep 2067,5716,36215,906-3,596
30 Jun 2065,7966,87015,120-3,568
31 Mar 2063,0057,77116,545-3,458
31 Dec 1963,1508,38513,910-3,001
30 Sep 1961,0778,52913,093-2,746
30 Jun 1958,5659,91912,449-2,757
31 Mar 1955,1449,05311,653-2,699
31 Dec 1851,5518,22011,087-2,421
30 Sep 1846,7226,96710,496-2,449
30 Jun 1843,1984,1089,862-1,993
31 Mar 1841,2343,7249,311-1,747
31 Dec 1738,7923,6958,708-1,522
30 Sep 1738,5894,4898,297-1,257
30 Jun 1738,3615,2687,846-1,324
31 Mar 1738,9116,1217,510-1,283
31 Dec 1640,48711,6337,458-1,472
30 Sep 1638,11010,9617,038-1,468
30 Jun 1636,5399,3886,665-1,378
31 Mar 1633,4745,5046,128-1,320
31 Dec 1532,9977,3678,595-202
30 Sep 1532,3257,2478,366-196
30 Jun 1531,5285,2078,223-272

質の高い収益: BIOCONには₹4.0B } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。

利益率の向上: BIOCONの現在の純利益率 (2.3%)は、昨年(6.6%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BIOCONの収益は過去 5 年間で年間2.7%増加しました。

成長の加速: BIOCONは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: BIOCONは過去 1 年間で収益成長率がマイナス ( -61.9% ) となったため、 Biotechs業界平均 ( 3.9% ) と比較することが困難です。

株主資本利益率

高いROE: BIOCONの 自己資本利益率 ( 1% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/11 02:06
終値2026/06/11 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Biocon Limited 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。39

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark